CY1110450T1 - Χρησιμοποιηση ενος παραγωγου αλογονιδιου υδροξιμικου οξεος στη θεραπευτικη αγωγη νευροεκφυλιστικων νοσων - Google Patents
Χρησιμοποιηση ενος παραγωγου αλογονιδιου υδροξιμικου οξεος στη θεραπευτικη αγωγη νευροεκφυλιστικων νοσωνInfo
- Publication number
- CY1110450T1 CY1110450T1 CY20081101426T CY081101426T CY1110450T1 CY 1110450 T1 CY1110450 T1 CY 1110450T1 CY 20081101426 T CY20081101426 T CY 20081101426T CY 081101426 T CY081101426 T CY 081101426T CY 1110450 T1 CY1110450 T1 CY 1110450T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- allogonide
- producer
- neurological diseases
- hydroximic acid
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 2
- SGEIEGAXKLMUIZ-PEZBUJJGSA-N (3z)-n-(2-hydroxy-3-piperidin-1-ylpropoxy)-1-oxidopyridin-1-ium-3-carboximidoyl chloride Chemical compound C1CCCCN1CC(O)CO\N=C(/Cl)C1=CC=C[N+]([O-])=C1 SGEIEGAXKLMUIZ-PEZBUJJGSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000203 mixture Chemical class 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
Abstract
Η εφεύρεση αναφέρεται στη χρησιμοποίηση μιας χημικής ουσίας επιλεγμένης από την ομάδα που περιλαμβάνει Ν-[2-υδροξυ-3-(1-πιπεριδινυλ)-προποξυ]-πυριδινο-1-οξειδο-3-καρβοξιμιδοϋλο χλωρίδιο, τα οπτικώς ενεργά εναντιομερή και τα μίγματα εναντιομερών αυτού και φαρμακευτικώς αποδεκτά άλατα των ρακεμικών και οπτικώς ενεργών ενώσεων στην παρασκευή μιας φαρμακευτικής σύνθεσης για τη θεραπευτική αγωγή ή πρόληψη νευροεκφυλιστικών νόσων.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0303584A HUP0303584A3 (en) | 2003-10-30 | 2003-10-30 | Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases |
| EP04791657A EP1696922B1 (en) | 2003-10-30 | 2004-10-25 | Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1110450T1 true CY1110450T1 (el) | 2015-04-29 |
Family
ID=89981738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20081101426T CY1110450T1 (el) | 2003-10-30 | 2008-12-10 | Χρησιμοποιηση ενος παραγωγου αλογονιδιου υδροξιμικου οξεος στη θεραπευτικη αγωγη νευροεκφυλιστικων νοσων |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US20080039497A1 (el) |
| EP (2) | EP2020233A3 (el) |
| JP (1) | JP5077997B2 (el) |
| KR (1) | KR20060103323A (el) |
| CN (1) | CN1901913A (el) |
| AT (1) | ATE409038T1 (el) |
| AU (1) | AU2004285343B2 (el) |
| BR (1) | BRPI0415625A (el) |
| CA (1) | CA2544332C (el) |
| CY (1) | CY1110450T1 (el) |
| CZ (1) | CZ2006347A3 (el) |
| DE (1) | DE602004016770D1 (el) |
| DK (1) | DK1696922T3 (el) |
| EA (1) | EA011301B1 (el) |
| ES (1) | ES2314458T3 (el) |
| HK (1) | HK1097438A1 (el) |
| HR (1) | HRP20080660T3 (el) |
| HU (1) | HUP0303584A3 (el) |
| IL (1) | IL175334A (el) |
| NO (1) | NO20062401L (el) |
| NZ (1) | NZ547216A (el) |
| PL (1) | PL1696922T3 (el) |
| PT (1) | PT1696922E (el) |
| SI (1) | SI1696922T1 (el) |
| UA (1) | UA86782C2 (el) |
| WO (1) | WO2005041965A1 (el) |
| ZA (1) | ZA200604376B (el) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ533795A (en) | 2002-01-11 | 2006-03-31 | Biorex Kutato Fejlesztoe Kft | Carboxamidine derivatives and their use in the treatment of vascular diseases |
| TW200831479A (en) * | 2006-09-26 | 2008-08-01 | Cytrx Corp | Pharmaceutical compositions and methods for treating diseases |
| CA3004867C (en) | 2008-06-26 | 2020-09-15 | Orphazyme Aps | Use of hsp70 as a regulator of enzymatic activity |
| EP2356988A4 (en) | 2008-11-18 | 2012-05-09 | Santen Pharmaceutical Co Ltd | THERAPEUTIC FOR CHORIORETINAL DEGENERATION WITH PYRIDINE-3-CARBALDEHYDE O- (PIPERIDIN-1-YL-PROPYL) OXIM DERIVATIVE AS ACTIVE SUBSTANCE |
| CA2817773A1 (en) | 2010-11-30 | 2012-06-07 | Orphazyme Aps | Methods for increasing intracellular activity of hsp70 |
| HUP1100534A2 (en) * | 2011-09-26 | 2013-04-29 | Balazs Dr Hazay | Pharmaceutical composition for the treatment of muscle atrophy |
| CN103804309B (zh) * | 2012-11-09 | 2019-08-02 | 广州喜鹊医药有限公司 | 一种氯肟类化合物及其制备方法和在制药中的应用 |
| KR102638203B1 (ko) * | 2014-09-15 | 2024-02-19 | 제브라 덴마크 에이/에스 | 아리모클로몰 제제 |
| EP3442530A1 (en) | 2016-04-13 | 2019-02-20 | Orphazyme A/S | Heat shock proteins and cholesterol homeostasis |
| BR112018070653A2 (pt) * | 2016-04-29 | 2019-02-05 | Orphazyme As | ingrediente farmacêutico ativo, e, composição |
| CN110753544A (zh) | 2017-05-24 | 2020-02-04 | 奥菲泽米有限公司 | 热激蛋白诱导物和额颞病况 |
| HUP1800298A1 (hu) | 2018-08-30 | 2020-05-28 | N Gene Res Laboratories Inc | Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére |
| JP2024500632A (ja) | 2020-11-19 | 2024-01-10 | ゼブラ デンマーク エー／エス | アリモクロモルクエン酸塩及びその中間体の調製プロセス |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU177578B (en) | 1976-08-27 | 1981-11-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing new 0-/3-amino-2-hydroxy-propyl/-amidoxime derivatives |
| DE2651083A1 (de) | 1976-11-09 | 1978-05-18 | Hoechst Ag | Neue o-alkylierte hydroxylamine, verfahren zu ihrer herstellung und ihre verwendung |
| HU207988B (en) * | 1988-10-20 | 1993-07-28 | Biorex Kutato Fejlesztoe Kft | Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components |
| HUT54347A (en) * | 1989-01-10 | 1991-02-28 | Chinoin Gyogyszer Es Vegyeszet | Improved process for producing amidoximes |
| US5334600A (en) * | 1991-07-30 | 1994-08-02 | Ciba-Geigy Corporation | Isoquinolyl substituted hydroxylamine derivatives |
| EP0758315B1 (en) | 1994-05-06 | 1998-08-26 | Biorex Kutato Es Fejlesztö Rt. | Novel hydroximic acid derivatives, pharmaceutical compositions containing them and process for preparing same |
| HU9502843D0 (en) * | 1995-09-29 | 1995-11-28 | Livigene Ltd | Pharmaceutical composition |
| HU222994B1 (hu) * | 1995-11-02 | 2004-01-28 | BIOREX Kutató és Fejlesztő Rt. | Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására |
| UA64716C2 (en) | 1996-08-09 | 2004-03-15 | Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells | |
| HU220971B1 (hu) | 1997-04-03 | 2002-07-29 | BIOREX Kutató és Fejlesztő Rt. | Eljárás 0-(3-amino-2-hidroxi-propil)-hidroximsav-halogenidek előállítására |
| UA65635C2 (uk) * | 1998-09-03 | 2004-04-15 | Н-Гене Кутато Кфт. | НЕНАСИЧЕНІ ПОХІДНІ ГІДРОКСИМОВОЇ КИСЛОТИ, ЩО МАЮТЬ ВЛАСТИВОСТІ ІНГІБІТОРІВ NAD<sup>+</sup>-ADP-РИБОЗИЛТРАНСФЕРАЗИ |
| HUP9900475D0 (en) * | 1999-02-26 | 1999-04-28 | Biorex Kutato Fejlesztoe Kft | O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component |
| HUP0001583A2 (hu) | 2000-04-18 | 2002-11-28 | BIOREX Kutató és Fejlesztő Rt. | Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké |
| HU0103939D0 (en) * | 2001-09-27 | 2001-11-28 | Biorex Kutato Fejlesztoe Kft | Pharmaceutical composition containing methformin and n-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride |
| ITMI20012573A1 (it) | 2001-12-06 | 2003-06-06 | D B P Dev Biotechonologica L P | Gli acilsalicilati:una nuova classe di induttori di risposta heat shock |
-
2003
- 2003-10-30 HU HU0303584A patent/HUP0303584A3/hu unknown
-
2004
- 2004-10-25 KR KR1020067010489A patent/KR20060103323A/ko not_active Application Discontinuation
- 2004-10-25 UA UAA200605899A patent/UA86782C2/ru unknown
- 2004-10-25 CA CA2544332A patent/CA2544332C/en not_active Expired - Fee Related
- 2004-10-25 NZ NZ547216A patent/NZ547216A/en unknown
- 2004-10-25 EP EP08157425A patent/EP2020233A3/en not_active Withdrawn
- 2004-10-25 EP EP04791657A patent/EP1696922B1/en active Active
- 2004-10-25 AU AU2004285343A patent/AU2004285343B2/en not_active Ceased
- 2004-10-25 CN CNA2004800396198A patent/CN1901913A/zh active Pending
- 2004-10-25 PL PL04791657T patent/PL1696922T3/pl unknown
- 2004-10-25 BR BRPI0415625-0A patent/BRPI0415625A/pt not_active Application Discontinuation
- 2004-10-25 ZA ZA200604376A patent/ZA200604376B/xx unknown
- 2004-10-25 US US10/582,124 patent/US20080039497A1/en not_active Abandoned
- 2004-10-25 CZ CZ20060347A patent/CZ2006347A3/cs unknown
- 2004-10-25 DK DK04791657T patent/DK1696922T3/da active
- 2004-10-25 DE DE602004016770T patent/DE602004016770D1/de active Active
- 2004-10-25 JP JP2006537449A patent/JP5077997B2/ja not_active Expired - Fee Related
- 2004-10-25 SI SI200430887T patent/SI1696922T1/sl unknown
- 2004-10-25 PT PT04791657T patent/PT1696922E/pt unknown
- 2004-10-25 AT AT04791657T patent/ATE409038T1/de active
- 2004-10-25 EA EA200600866A patent/EA011301B1/ru not_active IP Right Cessation
- 2004-10-25 ES ES04791657T patent/ES2314458T3/es active Active
- 2004-10-25 WO PCT/HU2004/000098 patent/WO2005041965A1/en active IP Right Grant
-
2006
- 2006-04-30 IL IL175334A patent/IL175334A/en not_active IP Right Cessation
- 2006-05-26 NO NO20062401A patent/NO20062401L/no not_active Application Discontinuation
-
2007
- 2007-03-06 HK HK07102495.9A patent/HK1097438A1/xx not_active IP Right Cessation
-
2008
- 2008-12-10 CY CY20081101426T patent/CY1110450T1/el unknown
- 2008-12-19 HR HR20080660T patent/HRP20080660T3/xx unknown
-
2011
- 2011-09-12 US US13/229,862 patent/US8962604B2/en not_active Expired - Fee Related
-
2015
- 2015-01-12 US US14/594,817 patent/US20150126551A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110450T1 (el) | Χρησιμοποιηση ενος παραγωγου αλογονιδιου υδροξιμικου οξεος στη θεραπευτικη αγωγη νευροεκφυλιστικων νοσων | |
| CY1113039T1 (el) | Ηλεκτρικο και μηλονικο αλας τρανς-4-(1r,3s)-6-χλωρο-3-φαινυλινδαν-1-υλο)-1,2,2-τριμεθυλοπιπεραζινης και η χρηση ως φαρμακο | |
| CY1115719T1 (el) | Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων | |
| EA200901373A1 (ru) | Аминогетероциклические соединения | |
| MXPA03011484A (es) | Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades. | |
| TW200624431A (en) | Phthalazinone derivatives, their manufacture and use as pharmaceutical agents | |
| FR2809396B1 (fr) | Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation | |
| EA200401114A2 (ru) | Замещённые гидроксиэтиламины | |
| ATE373474T1 (de) | Substituierte 2-aminotetraline zur behandlung von depressionen | |
| TW200531688A (en) | Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents | |
| DE602004008959D1 (de) | Benzoäbüä1,4üdioxepinderivate | |
| DK1641454T3 (da) | Pyrazolo[3,4-B]pyridin-6-oner som GSK-3-hæmmere | |
| ATE367387T1 (de) | Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden | |
| ATE403428T1 (de) | Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren | |
| NO20073176L (no) | Nye medikamenter for behandling av luftveissykdommer | |
| MXPA05005790A (es) | Aminoalcoxiindoles como ligandos del receptor 5-ht6 para el tratamiento de enfermedades del sistema nervioso central. | |
| SE0102440D0 (sv) | New compound | |
| HRP20050831A2 (en) | Novel oxazole derivatives, their manufacture and use as pharmaceutical agents | |
| ATE447953T1 (de) | Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis | |
| SE9900190D0 (sv) | New compounds | |
| ATE359995T1 (de) | Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit | |
| MXPA05011671A (es) | Nuevos derivados de anilina, su manufactura y su uso como agentes farmaceuticos. | |
| TW200509915A (en) | Novel oxazoles, their manufacture and use as pharmaceutical agents | |
| TW200626591A (en) | Amide derivatives, their manufacture and use as pharmaceutical agents | |
| UA108342C2 (uk) | Спосіб одержання 4-((1r,3s)-6-хлор-3-феніліндан-1-іл)-1,2,2-триметилпіперазину або його солі (варіанти), цис-(1s,3s)-6-хлор-3-феніліндан-1-ол, цис-(1s,3s)-3-заміщений-5-хлор-1-феніліндан та транс-1-((1r,3s)-6-хлор-3-феніліндан-1-іл)-3,3-диметилпіперазин |